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The work reported is part of an ongoing PhD study prompted by the particular 
difficulties encountered when two very different quality cultures interact (in this case 
Pharmaceutical industry clients and Construction industry providers). Pharmaceutical 
facilities have particular needs for their production requirements. Stringent 
regulations are set by regulatory bodies such as the Medicines and Healthcare 
products Regulatory Agency (MHRA) (in the UK) and the Food and Drugs 
Administration (FDA) in the US. This creates special problems of quality when it 
comes to the commissioning, validation and hand-over of the building, as it appears to 
be at odds with the rather less demanding quality systems that are normally accepted 
in the construction sector. The aim of the research is to model an acceptable process 
for incorporating these stringent validation requirements into the design, procurement 
and construction processes. There is little or no specific academic literature on the 
subject, though the trades and professional press (particularly in the USA) provide 
some normative comment on the problem area. The main academic grounding of the 
research is in Systems Theory and empirical data is being collecting using a multiple 
case study approach. Research data was collected from a number of pharmaceutical 
facility construction case studies and was used to test and inform a best practice 
model of facility validation. The qualitative methods of participant and direct 
observation were used as the main information gathering tools. The paper reports on 
the regulatory expectations that influence the construction of projects of this type and 
the impact on the best practice model of validation. 
Keywords: Quality, Commissioning, Validation, attitudes. 
INTRODUCTION 
Projects for the construction of pharmaceutical facilities differ from many 
construction projects because of the complex manufacturing processes housed within 
the facility and the critical nature of products that are produced. Tedesco & Titus 
(1995) suggest costs of items such as finishes, services installations, support systems, 
utilities and other hardware are far more significant than for non-pharmaceutical 
manufacturing facilities of equivalent size. Due to the nature of pharmaceutical 
products it is critical that the facility housing the production process complies with 
current regulatory requirements and performs its function perfectly from the very start 
of production, and even before. In order to demonstrate that facility compliance has 
been achieved there is a stringent validation process, and failure of the facility to 
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satisfy the relevant regulatory body will result in non-compliance, rendering the 
facility useless until it is remedied. 
AIM OF THE RESEARCH 
The reported research forms the early part of a PhD study. The aim of the study is to 
investigate the way that validation activities are currently accommodated within the 
process of constructing pharmaceutical facilities; to compare this with what should be 
done; and thereby to arrive at a model of best practice. In order to achieve this aim, 
the following paper objectives have been set: 
 
• define what constitutes validation of a pharmaceutical facility; 
• analyse the cultural views of the client and contactor in terms of project 
success criteria, project quality and regulatory compliance; 
• examine the implementation process and identify and explain those factors that 
influence the success of the validation activity; 
• assess what validation service provider models are commonly used and 
determine by the use of a research case study, the implications of the adopted 
approach. 
• establish what validation process stages typically occur and analyse the 
research data to establish if there is any deviation in content and timing from 
the third order validation cybernetic model. 
PROBLEM STATEMENT 
Despite the fact that facility validation is such a crucial element of pharmaceutical 
projects, it is still generally treated by the building team as an after-thought, an 
unpleasant duty to be performed at the end of commissioning, rather than something 
that is central to the construction process.  There is evidence of a 'clash of cultures' 
(Odum, 1992) that underlies the aspirations of the building's providers (designers and 
constructors) and those who have commissioned its use (the client). 
As a result, non-compliance, expensive re-work and project delay is common, and this 
leads to late plant start-up, delayed production, client dissatisfaction and, in some 
cases, ultimately litigation. However, these problems have received little or no 
research attention from those concerned with construction industry processes. Wheeler 
(1994) underlines the significance of this by noting that how we complete and 
handover our  buildings is as important as how we design and construct them.   
The validation process is based on providing documented proof, through testing, that 
the installed facility and systems, that are critical to the manufacturing process, 
consistently operate as specified. Testing procedures and strategies adopted in the 
industry seem to be based on past experience and company procedure and not on 
theoretical concepts. 
VALIDATION OF A PHARMACEUTICAL FACILITY 
To determine the key reasons why pharmaceutical facilities are validated and to 
determine what regulatory constraints are put on the construction industry a literature 
review was undertaken.    
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The literature on facility validation is almost exclusively produced by the healthcare 
technology industry, which includes pharmaceutical, biological and medical device 
manufacturing sectors. 
Various authors have recognized the effects of these regulations. De Valle (1995) 
suggests that factors such as plant geographical location and product market location 
have to be well understood to effectively manage the design, construction and 
validation of a pharmaceutical facility.  
Allan (2004) also found that the regulations have made validation costly and time-
consuming. In order to understand why these effects occur in the UK (European) and 
USA regulations have been analyzed, and the following sections report this analysis. 
UK AND EUROPEAN REGULATIONS 
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK 
regulatory agency responsible for ensuring that healthcare products and medical 
equipment meet the required standards.  
The Agency is an executive arm of the Department of Health. In April 2003 the 
MHRA replaced the Medicines Control Agency (MCA) and the Medical Devices 
Agency (MDA). 
The MHRA is the Competent Authority for medical devices and the pharmaceuticals 
Licensing Authority. The main activities of the agency are to enforce the requirements 
ensuring compliance to standards of pharmaceutical manufacture. 
In 1991 there was a harmonization of manufacturing authorizations and Good 
Manufacturing Practice (GMP) within the European Community and pharmaceutical 
inspections are now regulated by European Commission Directives. There are two 
main European Commission Directives that give the principles and guidelines of 
Good Manufacturing Practice (GMP). Directive 91/356/EEC gives information for 
medical products for human use and Directive 91/412/EEC gives information for 
veterinary medicinal products. 
Article 8 of the Rules, Guidance for Pharmaceutical Manufacturers and Distributors 
(MCA, 2002) states that ‘Premises and manufacturing equipment shall be located, 
designed, constructed and maintained to suit the intended operations’  
It goes on to say ‘Layout, design and operation must aim to minimize the risk of errors 
and permit effective cleaning and maintenance in order to avoid contamination, cross 
contamination and, in general any adverse effect on the quality of the product’ and 
‘Premises and equipment intended to be used for manufacturing operations which are 
critical for the quality of the products shall be subjected to appropriate qualification’.   
Qualification, or as it is also widely termed validation is ‘the action of proving, in 
accordance with the principles of GMP, that any procedure, process, equipment, 
material, activity or system actually leads to the expected results’ (MCA, 2002). The 
directives define those areas of specific importance as:- 
1. Avoidance of material or product contamination. 
2. Premises maintenance operations that do not present a hazard to the product quality. 
3. Appropriate lighting, temperature, humidity and Ventilation. 
4. Premises design to afford maximum protection against insects or other animals. 
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5. Prevention of entry of unauthorized people.  
The focus of this research is primarily concerned with items 1, 2 and 3 of the 
directives, as these are the areas that the construction industry has most influence and 
control over.  
The level of guidance that is given by the different regulatory authorities is general in 
nature and leaves the responsibility to the pharmaceutical manufacturer to provide 
documented evidence that the manufacturing facility is compliant with GMP. Quality 
therefore must be designed into the facilities and associated systems that will be used 
to produce the finished pharmaceutical drug product (Odum, 1997). The success of 
building in quality into a facility and hence the final drug product is dependant on the 
understanding of GMPs and the validation program. 
SUMMARY OF GMP REQUIREMENTS 
The study thus far has identified the main regulatory agencies, their expectations and 
their influence on the construction of pharmaceutical facilities.  Building on the 
definitions of the validation activity the goal is therefore to provide documented proof 
that: 
1. The premises, the facilities, the equipment and the processes have been designed in 
accordance with the requirements of current Good Manufacturing Practice (GMP). 
This represents the activity called Design Qualification (DQ). 
2. The facilities and equipment have been constructed and installed in compliance 
with their design specifications. This represents the activity called Installation 
Qualification (IQ). 
3. The facility and the equipment operate in accordance with their design 
specifications. This represents the activity called Operational Qualification (OQ). 
4. The facility and equipment operate within their design specification to repeatedly 
and reliably produce a finished product of the required quality. This represents the 
activity called   Process Qualification (PQ). It is essential that the construction and 
client teams operate in an integrated manner, sharing their specialist knowledge, with 
the common goal of regulatory compliance. 
MODEL DEVELOPMENT 
Together with the understanding and interpretation of the main regulatory 
requirements there are a number of other success related factors that will have an 
effect on the project outcome. The success factors at this stage are partly developed 
independent hypothetical propositions that may or may not be directly influential.  Yin 
(1994), argues that each proposition directs focus on an area to be examined and each 
specific proposition may assist in enclosing the study within reasonable boundaries. 
The success factors are not exhaustive and by the process of interpretivist methods 
(Bryman, 1988) may lead to the generation of others.  This then leads to the following 
model of Pharmaceutical Facility Validation (See Figure 1). 
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Figure 1:  Validation Cybernetic System Model (Third Order) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The validation process model can be viewed as an open system. The system, of the 
type described by Yolles, (1999) comprises of input, a process and an output.  Roper, 
(1994) describes open systems as having no mechanism for comparison of the output 
and input and are termed black box systems. The introduction of a feedback loop, 
sensor and comparator allows direct comparison of output with input. This 
comparison will result in the observation of deviation and is known as a white box 
system. 
In the same way the validation process can be considered in similar terms where the 
desired system output is GMP compliance, the input is the validation test stimuli and 
the process is the implementation model. The introduction of a feedback loop, sensor 
and comparator introduce the ability to provide cybernetic control. The term 
cybernetic comes from the ancient Greek word Kubernesis which means ‘steering’ or 
‘governing’.  
To provide sufficient validation system testing coverage, black box or functional 
system analysis alone would not be a suitable system model. The combination of 
structural or white box techniques and functional analysis would provide a more 
suitable model. 
 It is recognized that the utilization of sufficient validation test procedures and 
 testing concepts will be fundamental in achieving project success. Therefore, other  
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 industries that have similar characteristics to the pharmaceutical industry (i.e. 
 technically complex processes, with the requirement for system testing to provide  
assurance of project quality) have been additionally investigated in the research. The 
main aim is to determine if there are any highly developed testing and implementation 
solutions currently being used that could be applicable to the provision of 
pharmaceutical buildings. The open system view of validation, as part of the 
construction process, also leads to the system being open to the local environment at 
the system boundary. Success factors, as identified in figure 1, will be acting at this 
boundary. The negative feedback is based on circular causal chain mechanisms 
monitoring and feeding back information on deviations from the goal. 
The model represents a sequential set of activities that are time series dependant. Each 
activity can only commence once the previous one is completed. Best practice project 
completion point is represented by C1and C2 represents the actual completion of the 
project in the termination phase. The deviation between C1 and C2   can be seen as the 
measurement of the absence of in-built quality and time delay. Allan (2004) has 
examined downstream problems of this type. He has found that cost can escalate and 
schedules can extend due to the failure of construction organization to integrate and to 
produce quality documentation.   It is proposed that the reason for deviation from best 
practice is related to those factors acting at the system boundary. 
RESEARCH STRATEGY 
Participant Observation 
Two main research strategies identified by Glaser and Strauss, (1967) are verification 
and generation. Verification, positivist (Easterby -Smith et al, 1991) or logico-
deductive strategies relate to proposition or hypothesis testing. These are most 
commonly associated with empirical data that is quantitative. 
Generation or interpretivist methods of research rely on allowing theory to emerge 
from the data; and there is a tendency for such data to be of a qualitative nature 
(Bryman, 1988).  The nature of the study problem has shaped the research strategy. 
The limited amount of existing theory published on the subject pointed to the need to 
employ an almost exclusively qualitative empirical study. According to Jorgensen 
(1989) use of participant observation is particularly applicable to research problems 
where little is known about the problem being studied and the phenomenon is 
somehow obscured from the views of the outsider. In essence human studies require a 
unique methodology that allows the observer to be placed in the everyday setting of 
the observed. Therefore a case study was undertaken with the researcher adopting the 
research methodology of participant observation. 
Case Study and Questionnaire 
The two main data collection methods employed in the research have been:- 
1. Site based participant observation, as a member of a validation team within a 
pharmaceutical manufacturing company’s quality assurance department. 
2. An industry questionnaire. 
The case study project was the construction of a pharmaceutical pilot plant which 
comprised of a tablet compression suite, tablet coating suite and packaging hall. The 
data collection methods used were interviews with the construction project manager 
and validation manager, collection of observation notes in the form of a case study 
diary, memos, reports, validation protocols, letters, and informal interviews. Once the 
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research data was collected it was then analyzed. This was done by breaking the data 
into segments that were of a controllable size, that allow the identification of patterns, 
sequences, classes, types or processes. The analysis process then consisted of 
assembling the data in such a way that permitted comprehension or meaning to be 
derived from the data.  
By piecing together the research findings in this way and making sense of them, the 
process of theory building or theorizing takes place. Jorgensen, (1997) describes 
theorizing as ‘an arrangement of facts in the form of an explanation or interpretation’. 
To supplement the fieldwork an industry questionnaire was sent to construction and 
pharmaceutical practitioners. The survey was used specifically as a sampling tool to 
gauge the attitudes and views of both study groups. This mixed mode research was 
used to help provide what Yin (1994) terms converging lines of enquiry. 
RESULTS 
Case Study Findings 
The findings below are a summary of a number of generalizations that came from the 
site-based research: -   
 
• Experience - The main contractor demonstrated a limited knowledge of the 
pharmaceutical industry. This lack of understanding stemmed from limited 
experience of this project type and no formal education within the subject area.  
It became evident that there are wide cultural difference between 
pharmaceutical manufacture and construction working practices.  
• Service Provider Model – The validation specialist employed by the 
pharmaceutical client was not sufficiently experienced in 
construction/engineering disciplines to create suitable validation test protocols. 
The specialist’s background was related to process engineering and not facility 
construction. 
• Validation Process – The client failed to appoint the validation specialist until 
after construction had commenced. This resulted in problems associated with 
the sequencing of validation tasks. 
• Risk – The main contractor viewed the validation works as specialist and 
therefore an area of high financial risk. This view was   based partly on 
previous experience of providing validation assistance as an un-charged extra. 
• The commissioning activity became the project phase for carrying out nearly 
all of the validation works.  The commissioning and validation teams did not 
work as an integrated team and expensive re-witnessing tests were required. 
• Regulatory expectations – Those involved appeared to be unclear of levels to 
be achieved. The team member who had the greatest experience in this area 
was the client validation manager. Unfortunately, the validation manager was 
not part of the core project group.  
• Communications – Project progress meetings were too time consuming and 
were attended by too many different disciplines. As a result it became difficult 
for the main contractor to progress the project whilst waiting for specific issues 
and problems to be addressed.  
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• Some Good Manufacturing Practice issues were not included in the initial 
project design and they were not discovered until after project completion. The 
main reason for this was that a design review exercise was not carried out. 
 The main problems associated with timing and implementation that have informed the 
 third order cybernetic systems model have been identified as:- 
1. Incomplete and unsuitable User Requirement Specification (URS). 
2. Inadequate resultant Functional Specification (FS). 
3. Absence of a Validation Master Plan (VMP).  
4. Missing validation process stages. 
5. Non-sequential validation process. 
6. Validation process occurring post construction project. 
7. Change control – inability to accommodate project change and prevention of post 
project GMP non-compliance. 
CONCLUSIONS 
The criteria by which the success of any construction project is judged are normally 
time, cost and quality. Time and cost are readily measurable, but the meaning of 
quality can be more elusive, and this is at the root of the problem of successful 
validation of pharmaceutical buildings. During the research, it has become clear that 
construction project managers probably tend to understand quality as a measure of 
workmanship, while pharmaceutical project managers view it in terms of assurance 
and regulatory compliance. This difference in understanding and the importance of the 
construction project managers input into the validation activity has been overlooked or 
at best underestimated.  
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